Tag: Atrial Fibrillation

ClearFlow Release: Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery

Feb. 1, 2018 19:16 UTC –ClearFlow spokespeople cite review article as latest piece of mounting evidence pertaining to urgent need for managing retained blood after surgery– ANAHEIM, Calif.–(BUSINESS WIRE)– ClearFlow, a medical device company based in Anaheim, CA., has announced that the cover of the January 2018 issue of The Annals of […]

First Patient Enrolled in U.S. IDE Study To Evaluate the Potential of New Device To Reduce Stroke Risk in Atrial Fibrillation Patients

IRVINE, Calif., Jan. 11, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* today announced that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, enrolled the first patient in the WaveCrest® Investigational Device Exemption (IDE) Trial. The study will evaluate the safety and effectiveness of the WaveCrest® Left Atrial […]

Clinical study validates efficiencies of Stereotaxis Niobe ES system compared to Niobe II system

ST. LOUIS, March 14, 2017 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported results of a study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France, which validates the advantages of the Niobe ® ES magnetic navigation […]

AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. “I am honored and humbled to be […]